Observational (Non-interventional), Follow-up Trial Assessing Long-term Local Tolerability and Efficacy (Recurrence Rate) of Resiquimod Gel in Patients Treated for Actinic Keratosis.

Efficacy Evaluation: • Primarily based on clinical inspection of the former 25 cm2 treatment area and count of the AK-lesions. Safety Evaluation: Evaluation of adverse events (AEs) and serious adverse events (SAEs) Evaluation of newly occurred dermal adverse events (AEs) and serious adverse events (SAEs) in the previous treatment area at 6 months and 12 months of follow-up (local tolerability). Follow-up of unresolved adverse and serious adverse events that occurred in the previous trial SP848-AK-1101. Follow-up of unresolved abnormal laboratory values that occurred in the previous trial SP848-AK-1101.